Analysts expect that Aphria Inc (NYSE:APHA) will report sales of $103.90 million for the current fiscal quarter, according to Zacks. Two analysts have made estimates for Aphria’s earnings. The lowest sales estimate is $103.44 million and the highest is $104.35 million. Aphria posted sales of $10.15 million in the same quarter last year, which would indicate a positive year-over-year growth rate of 923.6%. The company is expected to announce its next quarterly earnings report on Friday, October 11th.
Receive News & Ratings for Aphria Daily Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aphria and related companies with MarketBeat.com's FREE daily email newsletter
According to Zacks, analysts expect that Aphria will report full-year sales of $503.75 million for the current fiscal year, with estimates ranging from $494.91 million to $514.18 million. For the next year, analysts forecast that the company will report sales of $709.97 million, with estimates ranging from $667.09 million to $766.81 million. Zacks Investment Research’s sales averages are a mean average based on a survey of sell-side research analysts that follow Aphria.
Aphria (NYSE:APHA) last announced its quarterly earnings results on Thursday, August 1st. The company reported $0.05 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($0.05) by $0.10. The firm had revenue of $128.60 million during the quarter, compared to the consensus estimate of $99.26 million. The company’s revenue for the quarter was up 971.7% on a year-over-year basis.
A number of brokerages recently issued reports on APHA. CIBC cut shares of Aphria from a “neutral” rating to a “sector underperform” rating in a research note on Friday, July 26th. Zacks Investment Research cut shares of Aphria from a “strong-buy” rating to a “hold” rating in a research note on Thursday, August 22nd. Jefferies Financial Group began coverage on shares of Aphria in a research note on Friday, May 24th. They issued a “buy” rating and a $11.00 price target on the stock. Finally, ValuEngine upgraded shares of Aphria from a “hold” rating to a “buy” rating in a research note on Thursday, August 1st. One equities research analyst has rated the stock with a sell rating, two have given a hold rating and six have given a buy rating to the stock. Aphria presently has a consensus rating of “Buy” and a consensus price target of $13.63.
Shares of Aphria stock opened at $6.45 on Friday. The stock has a market cap of $1.58 billion, a price-to-earnings ratio of -58.64 and a beta of 3.07. The firm’s 50-day moving average is $6.31 and its 200 day moving average is $7.76. Aphria has a 1 year low of $3.75 and a 1 year high of $16.86.
A number of institutional investors and hedge funds have recently bought and sold shares of the business. ETF Managers Group LLC bought a new position in Aphria during the 2nd quarter valued at about $48,941,000. Vanguard Group Inc. lifted its stake in Aphria by 2.6% during the 2nd quarter. Vanguard Group Inc. now owns 5,402,302 shares of the company’s stock valued at $37,870,000 after acquiring an additional 135,714 shares during the period. Connor Clark & Lunn Investment Management Ltd. lifted its stake in Aphria by 1,307.8% during the 1st quarter. Connor Clark & Lunn Investment Management Ltd. now owns 1,057,811 shares of the company’s stock valued at $9,866,000 after acquiring an additional 982,671 shares during the period. Bank of America Corp DE lifted its stake in Aphria by 410.2% during the 2nd quarter. Bank of America Corp DE now owns 507,034 shares of the company’s stock valued at $3,554,000 after acquiring an additional 407,658 shares during the period. Finally, Swiss National Bank lifted its stake in Aphria by 8.0% during the 2nd quarter. Swiss National Bank now owns 445,400 shares of the company’s stock valued at $3,132,000 after acquiring an additional 33,000 shares during the period. Institutional investors and hedge funds own 8.46% of the company’s stock.
Aphria Company Profile
Aphria Inc produces and sells medical cannabis in Canada and internationally. The company offers sativa, indica, and hybrid medical marijuana products, as well as cannabis oils. It serves patients and health professionals. The company also sells its products online. Aphria Inc is headquartered in Leamington, Canada.
glta and a continued great weekend!
$$$$$APHA$$$$$
$inai